Overall, these data suggest that inclusion of CD4 and CD8 T cells that recognize tumor antigens presented by major histocompatibility class II (MHCII) and MHCI may be a good therapeutic strategy to generate effective TIL ACT products, which is a term for expanded and activated TILs ready for infusion into a patient. Here, CD4 is linked to neoplasm.